Search Result

Results for "

ML 2-14

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (2) CDK (1) COX (1) Dengue virus (1) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) EGFR (1) Epigenetic Reader Domain (1) Flavivirus (1) Glucocorticoid Receptor (3) HDAC (1) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (2) JAK (1) JNK (2) LXR (1) MAGL (1) MicroRNA (16) Monoamine Oxidase (2) mTOR (3) NOD-like Receptor (NLR) (1) Parasite (1) Phosphodiesterase (PDE) (2) Polo-like Kinase (PLK) (2) Potassium Channel (1) PROTAC Linkers (1) SARS-CoV (2) SGK (1) SGLT (1) Small Interfering RNA (siRNA) (3) Tyrosinase (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (2) Endocrinology (2) Infection (2) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (5)

By Targets:

Apoptosis (1)

Autophagy (2)

CDK (1)

COX (1)

Dengue virus (1)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

EGFR (1)

Epigenetic Reader Domain (1)

Flavivirus (1)

Glucocorticoid Receptor (3)

HDAC (1)

iGluR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (2)

JAK (1)

JNK (2)

LXR (1)

MAGL (1)

MicroRNA (16)

Monoamine Oxidase (2)

mTOR (3)

NOD-like Receptor (NLR) (1)

Parasite (1)

Phosphodiesterase (PDE) (2)

Polo-like Kinase (PLK) (2)

Potassium Channel (1)

PROTAC Linkers (1)

SARS-CoV (2)

SGK (1)

SGLT (1)

Small Interfering RNA (siRNA) (3)

Tyrosinase (1)

By Research Areas:

Cancer (18)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (10)

Metabolic Disease (7)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132991

ML 2-14

PROTAC Linkers Cancer

ML 2-14 is a PROTAC for degrading BRD4, with C4 alkyl linker. ML 2-14 exerts degradation of BRD4 in 231MFP breast cancer cells .

ML 2-14	PROTAC Linkers	Cancer
ML 2-14 is a PROTAC for degrading BRD4, with C4 alkyl linker. ML 2-14 exerts degradation of BRD4 in 231MFP breast cancer cells .

HY-12501A

ITI-214 3 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease
ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (K_i of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with K_is of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions .

HY-158116

VVD-214 RO7589831; VVD-133214	DNA/RNA Synthesis	Cancer
VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers.

HY-150553

COX-2-IN-28

COX Inflammation/Immunology

COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC₅₀ values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .

COX-2-IN-28	COX	Inflammation/Immunology
COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC₅₀ values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .

HY-12501

*ITI-214* free base**	Phosphodiesterase (PDE)	Neurological Disease
ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (K_i of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with K_is of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions .

HY-12045

HMN-214 4 Publications Verification IVX-214	Polo-like Kinase (PLK)	Cancer
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

HY-100753

STAT3-IN-1 Maximum Cited Publications 8 Publications Verification
STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC₅₀ values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis .

HY-145931

CC214-2	mTOR Autophagy	Cancer
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .

HY-154910

CC214-1	mTOR	Cancer
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC₅₀ is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study .

HY-RS12079

RNF214 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RNF214 Human Pre-designed siRNA Set A contains three designed siRNAs for RNF214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RNF214 Human Pre-designed siRNA Set A RNF214 Human Pre-designed siRNA Set A

HY-RS14698

TMEM214 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TMEM214 Human Pre-designed siRNA Set A contains three designed siRNAs for TMEM214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TMEM214 Human Pre-designed siRNA Set A TMEM214 Human Pre-designed siRNA Set A

HY-RS09692

NUP214 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NUP214 Human Pre-designed siRNA Set A contains three designed siRNAs for NUP214 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NUP214 Human Pre-designed siRNA Set A NUP214 Human Pre-designed siRNA Set A

HY-P3813

*Tyrosinase (206-214), human*	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P4149

Imsamotide IDO194-214	Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology Cancer
Imsamotide (IDO194-214) is a Indoleamine 2,3-Dioxygenase (IDO) peptide with sequences of DTLLKALLEIASCLEKALQVF, the IDO194-214. Imsamotide is also an immunological agent for active immunization, as well as an antineoplastic agent .

HY-14945

Remogliflozin etabonate GSK189075	SGLT	Metabolic Disease
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

HY-144761

TOPK-p38/JNK-IN-1	JNK	Cancer
TOPK-p38/JNK-IN-1 (Compound B12) is an orally active TOPK-p38/JNK signaling pathway inhibitor with the IC₅₀ value of 2.14 µM for NO production. TOPK-p38/JNK-IN-1 shows anti-inflammatory activities. TOPK-p38/JNK-IN-1 also inhibits phosphorylate downstream related proteins and avoids degradation of TOPK .

HY-124582

NEO214	Autophagy mTOR	Cancer
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .

HY-147860

EGFR-IN-61	EGFR	Cancer
EGFR-IN-61 (compound 22a) is a potent EGFR kinase inhibitor, with IC₅₀ values of 42 nM (L858R/T790 M), 137 nM (L858R/T790 M/C797S), and 743 nM (WT), respectively. EGFR-IN-61 shows antiproliferative activity against A549 and H1975 cell lines, with IC₅₀ values of 2.14 and 1.82 μM, respectively .

HY-W010668

Quinine sulfate hydrate 2 Publications Verification	Flavivirus Dengue virus Parasite Potassium Channel	Others
Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (K_Ca5.1) channel currents evoked by voltage pulses to +100 mV with an IC₅₀ of 169 μM .

HY-101442

SR9238

LXR Metabolic Disease

SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC₅₀s of 214 nM and 43 nM for LXRα and LXRβ, respectively.

SR9238	LXR	Metabolic Disease
SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC₅₀s of 214 nM and 43 nM for LXRα and LXRβ, respectively.

HY-108597

TC-S 7005 1 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

HY-R00445

*hsa-miR-214-3p mimic*	MicroRNA	Cancer
hsa-miR-214-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-214-3p mimic hsa-miR-214-3p mimic

HY-R00446

*hsa-miR-214-5p mimic*	MicroRNA	Cancer
hsa-miR-214-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-214-5p mimic hsa-miR-214-5p mimic

HY-R04303

*rno-miR-214-3p mimic*	MicroRNA	Cancer
rno-miR-214-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-214-3p mimic rno-miR-214-3p mimic

HY-R04304

*rno-miR-214-5p mimic*	MicroRNA	Cancer
rno-miR-214-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-214-5p mimic rno-miR-214-5p mimic

HY-145408

CDK7/9-IN-1	CDK	Cancer
CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC₅₀s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC₅₀ of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer .

HY-163159

NP3-562	NOD-like Receptor (NLR)	Inflammation/Immunology
NP3-562 is a potent, orally active, tricyclic NLRP3 Inhibitor, with an IC₅₀ of 214 nM. NP3-562 (30 mg/kg, p.o.) inhibits IL-1β release in a mouse acute peritonitis model .

HY-150053

JNK-IN-11	JNK	Neurological Disease
JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC₅₀ value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .

HY-B1402B

Hydrocortisone hemisuccinate sodium Hydrocortisone 21-hemisuccinate sodium	Glucocorticoid Receptor	Metabolic Disease
Hydrocortisone hemisuccinate sodium is an orally active physiological glucocorticoid. Hydrocortisone hemisuccinate sodium inhibits proinflammatory cytokine activity, with IC₅₀s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate sodium can be used for the research of ulcerative colitis (UC) .

HY-B1155

Hydrocortisone phosphate Hydrocortisone 21-phosphate; Cortisol 21-phosphate	Glucocorticoid Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology Endocrinology
Hydrocortisone phosphate (Hydrocortisone 21-phosphate), a physiological glucocorticoid, and is an orally active steroidal anti-in ammatory agent (SAID). Hydrocortisone phosphate inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone phosphate can be used for the research of ulcerative colitis (UC).

HY-RI00445

*hsa-miR-214-3p inhibitor*	MicroRNA
hsa-miR-214-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-214-3p inhibitor hsa-miR-214-3p inhibitor

HY-RI00446

*hsa-miR-214-5p inhibitor*	MicroRNA
hsa-miR-214-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-214-5p inhibitor hsa-miR-214-5p inhibitor

HY-RI04303

*rno-miR-214-3p inhibitor*	MicroRNA
rno-miR-214-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-214-3p inhibitor rno-miR-214-3p inhibitor

HY-RI04304

*rno-miR-214-5p inhibitor*	MicroRNA
rno-miR-214-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-214-5p inhibitor rno-miR-214-5p inhibitor

HY-150681

SARS-CoV-2 nsp14-IN-2	SARS-CoV	Infection
SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC₅₀ value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19 .

HY-155119

SARS-CoV-2-IN-54	SARS-CoV	Infection
SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC₅₀ of 21.4 μM .

HY-136571

GSK046 2 Publications Verification iBET-BD2	Epigenetic Reader Domain	Inflammation/Immunology
GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins, with IC₅₀s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively. GSK046 has immunomodulatory activity .

HY-B1402

Hydrocortisone hemisuccinate 1 Publications Verification Hydrocortisone 21-hemisuccinate
Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-in ammatory agent (SAID). Hydrocortisone hemisuccinate inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate can be used for the research of ulcerative colitis (UC).

HY-145845

HDAC1/MAO-B-IN-1	HDAC Monoamine Oxidase	Neurological Disease
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier HDAC1/MAO-B inhibitor with IC₅₀ values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease .

HY-101311

UPF-523 AIDA
UPF-523 (AIDA), a rigid (carboxyphenyl) glycine derivative, is a relatively potent and selective antagonist of group I metabotropic glutamate receptors (mGlu1a) with an IC₅₀ of 214 μM. But UPF-523 has no effect on group II (mGlu2), group III (mGlu4) receptors or ionotropic glutamate receptors. UPF-523 has the potential for the research of the acute arthritis .

HY-R00445A

*hsa-miR-214-3p agomir*	MicroRNA
hsa-miR-214-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-214-3p agomir hsa-miR-214-3p agomir

HY-R00446A

*hsa-miR-214-5p agomir*	MicroRNA
hsa-miR-214-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-214-5p agomir hsa-miR-214-5p agomir

HY-R04303A

*rno-miR-214-3p agomir*	MicroRNA
rno-miR-214-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-214-3p agomir rno-miR-214-3p agomir

HY-R04304A

*rno-miR-214-5p agomir*	MicroRNA
rno-miR-214-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-214-5p agomir rno-miR-214-5p agomir

HY-B1402R

Hydrocortisone hemisuccinate (Standard) Hydrocortisone 21-hemisuccinate (Standard)	Glucocorticoid Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology Endocrinology
Hydrocortisone hemisuccinate (Standard) is the analytical standard of Hydrocortisone hemisuccinate. This product is intended for research and analytical applications. Hydrocortisone hemisuccinate (Hydrocortisone 21-hemisuccinate), a physiological glucocorticoid, is an orally active steroidal anti-in ammatory agent (SAID). Hydrocortisone hemisuccinate inhibits proinflammatory cytokine activity, with IC50s of 6.7 and 21.4 μM for IL-6 and IL-3, respectively. Hydrocortisone hemisuccinate can be used for the research of ulcerative colitis (UC).

HY-136584

*2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid*	Others	Cardiovascular Disease Metabolic Disease
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders .

HY-N3991

14β-Benzoyloxy-2-deacetylbaccatin VI	Others	Others
14β-Benzoyloxy-2-deacetylbaccatin VI is a xetane-ring-containing taxoid compound isolated from the leaves and stems of Taxus chinensis .

HY-RI00445A

*hsa-miR-214-3p antagomir*	MicroRNA
hsa-miR-214-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-214-3p antagomir hsa-miR-214-3p antagomir

HY-RI00446A

*hsa-miR-214-5p antagomir*	MicroRNA
hsa-miR-214-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-214-5p antagomir hsa-miR-214-5p antagomir

HY-RI04303A

*rno-miR-214-3p antagomir*	MicroRNA
rno-miR-214-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-214-3p antagomir rno-miR-214-3p antagomir

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks